In third deal under Miels, GSK adds targeted cancer therapies via $10.6B Nuvalent buy

GSK’s $10.6 billion acquisition of Nuvalent, its third and largest M&A transaction since Luke Miels became CEO this year, will give the pharma two registrational products for targeted lung cancer populations while also paving the way for it to commercialize a high-priority internal program in late-stage testing.

Pending its completion, the deal will give GSK plc (LSE:GSK; NYSE:GSK) ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib. Both are under FDA review based on pivotal data in non-small cell lung cancer (NSCLC) patients who have received tyrosine kinase inhibitors previously; Nuvalent Inc. (NASDAQ:NUVL) is also testing them in TKI-naive patients...